glutamate ionotropic receptor NMDA type subunit 3BGenealiases: GluN3B · NR3B
Q-omics provides the consensus-scored GRIN3B profile across patient tissues and cancer cell-line models. GRIN3B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GRIN3B is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, GRIN3B RNA expression shows 17,422 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where GRIN3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIN3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIN3B survival associations across molecular data types. GRIN3B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIN3B RNA expression–survival associations across cancer types. High GRIN3B expression shows unfavorable associations in KIRC, ACC, MESO, COAD and UVM, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GRIN3B RNA expression.
This table summarizes GRIN3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GRIN3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIN3B shows lower tumor expression in LUSC and higher tumor expression in COAD, BLCA, HNSC, THCA and STAD. The COAD box plot shows higher GRIN3B RNA expression in tumor versus normal tissue (log2 FC = +0.564, t-test p < 0.001).
This table shows molecular features associated with GRIN3B in patient tissues and cancer cell lines. In patient samples, GRIN3B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIN3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
